Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As AbbVie’s Challenge Falters, Vertex Looks To Build On CF Dominance

Blockbuster Potential In Late-Stage Pipeline

Executive Summary

Vertex is likely to have the cystic fibrosis market to itself for years to come, but investors are banking on it repeating that success in several new first-in-class therapy areas.

You may also be interested in...



Moderna Spotlights Lung Delivery As One Of Its mRNA 'Dreams'

The company’s emphasis on artificial intelligence has played a leading role in development of lipid nanoparticles enabling delivery of mRNA to lung tissue under a partnership with Vertex.

Vertex Diabetes Cell Therapy Trial On Hold – As First Patient Free From Insulin Injections

Vertex expresses surprise at the US FDA’s call for a halt, as it reveals an exciting milestone reached - the first trial participant now producing their own insulin.

Vertex Is The First To Get NaV1.8 To Proof Of Concept For Pain

Chief scientific officer David Altshuler talked to Scrip about the late-stage development plan for a drug that could represent a blockbuster-sized commercial opportunity, after two Phase II studies testing VX-548 met their primary endpoints.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC146336

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel